Title

Cannabidiol for Anxiety
Prospective Evaluation of Cannabidiol (CBD) on Anxiety: A Pilot Study
  • Phase

    Phase 2
  • Study Type

    Interventional
  • Status

    Withdrawn
  • Study Participants

    0
This pilot trial seeks to investigate the effect of 25 mg full-spectrum CBD soft gel capsules (up to a total dosage of 100mg per day) on individuals with diagnosed anxiety. All participants will take CBD soft gel capsules for 12 weeks, and will be assessed at 6 weeks and 12 weeks post-enrollment using measures of anxiety, sleep and perception of change.
Study Started
Mar 01
2020
Primary Completion
Dec 01
2020
Study Completion
Dec 01
2020
Last Update
Dec 19
2020

Drug Cannabidiol

25 mg full-spectrum CBD soft gel capsules

Cannabidiol Experimental

Participants will take 25 mg full-spectrum CBD soft gel capsules (2 to 4 per day) for 12 weeks.

Criteria

Male or female patients 18 years of age or older with a GAD-7 score of 10 or greater
Presenting to a participating clinic for initial evaluation for a medical cannabis card
Willingness to abstain from the use of all other cannabis products for the trial period (3 months)
Not pregnant or planning to become pregnant during the trial period (3 months)
Not breastfeeding or planning to breastfeed during the trial period (3 months)
No history of cannabis use within 4 weeks of enrollment
No history of lifetime cannabis use disorder or other substance use disorders (except: tobacco use disorder)
No history of lifetime daily cannabis use
No family history of psychosis (e.g., bipolar disorder or schizophrenia)
No history of adverse reactions to cannabis
No recent changes to prescribed anxiety medications (within the last 1 month)
Provision of informed consent
No Results Posted